红景天注射液联合阿奇霉素治疗儿童肺炎支原体感染的疗效及安全性：系统评价和荟萃分析。
Efficacy and safety of reduning injection combined with azithromycin in the treatment of mycoplasma pneumonia among children: A systematic review and meta-analysis.
机构信息
Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning Province, China.
Sanya Women and Children's Hospital, managed by Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Sanya, Hainan Province, China.
出版信息
Phytomedicine. 2022 Nov;106:154402. doi: 10.1016/j.phymed.2022.154402. Epub 2022 Aug 21.
BACKGROUND
Reduning (RDN) injection is a well-known traditional Chinese medicine (TCM) preparation that can be used as an alternative to antibiotics with synergistic and toxicity-reducing effects. In China, RDN is widely used in the combined treatment of infectious diseases.
OBJECTIVE
To evaluate the clinical efficacy of RDN combined with azithromycin (AZM) for the treatment of mycoplasma pneumonia (MP) among children and to determine its safety, providing an evidence-based reference for clinical treatment.
METHODS
Eight databases were searched, including 4 English databases, namely, PubMed, EMBASE, the Cochrane Library, and Web of Science, and 4 Chinese databases, namely, China National Knowledge Infrastructure (CNKI), Wanfang, China Science and Technology Journal Database (CQVIP), and Sino-Med. Randomized controlled trials (RCTs) were included in which RDN was combined with AZM for the treatment of MP pediatric patients. A comprehensive search was performed from the inception of each database until April 25, 2022.
RESULTS
A total of 20 studies covering 1628 children were included. Meta-analysis showed that the clinical effectiveness rate (RR = 1.20, 95% CI [1.15, 1.26], I = 0%), time elapsed until disappearance of cough (MD = -2.04, 95% CI [-2.67, -1.41], I = 91%), time elapsed until disappearance of lung rales (MD = -2.55, 95% CI [-3.12, -1.98], I = 95%), time elapsed until reduction of fever (MD = -1.93, 95% CI [-2.37, -1.49], I = 92%), TNF-α level after treatment (SMD = -1.17, 95% CI [-1.96, -0.39], I = 97%), and IL-6 levels after treatment (SMD = -2.65, 95% CI [-3.51, -1.78], I = 97%) of the combined treatment of MPP were superior to those of other methods, and incidence of adverse reactions (RR = 0.75, 95% CI [0.56, 1.00], I = 0%) showed statistically significant differences.
CONCLUSION
RDN combined with AZM for the treatment of MP among children results in increased clinical efficacy with high safety.
背景
热毒宁（RDN）注射液是一种著名的中药制剂，具有协同作用和降低毒性的特点，可作为抗生素的替代品。在中国，RDN 广泛用于传染病的联合治疗。
目的
评价热毒宁联合阿奇霉素（AZM）治疗儿童肺炎支原体（MP）的临床疗效，并确定其安全性，为临床治疗提供循证参考。
方法
检索 8 个数据库，包括 4 个英文数据库，即 PubMed、EMBASE、Cochrane 图书馆和 Web of Science，以及 4 个中文数据库，即中国知网（CNKI）、万方、中国科技期刊数据库（CQVIP）和 SinoMed。纳入热毒宁联合 AZM 治疗儿童 MP 患者的随机对照试验（RCT）。从每个数据库的成立之初到 2022 年 4 月 25 日进行全面搜索。
结果
共纳入 20 项研究，涵盖 1628 名儿童。Meta 分析显示，临床有效率（RR=1.20，95%CI[1.15，1.26]，I=0%）、咳嗽消失时间（MD=-2.04，95%CI[-2.67，-1.41]，I=91%）、肺部啰音消失时间（MD=-2.55，95%CI[-3.12，-1.98]，I=95%）、退热时间（MD=-1.93，95%CI[-2.37，-1.49]，I=92%）、治疗后 TNF-α 水平（SMD=-1.17，95%CI[-1.96，-0.39]，I=97%）和治疗后 IL-6 水平（SMD=-2.65，95%CI[-3.51，-1.78]，I=97%）均优于其他方法，不良反应发生率（RR=0.75，95%CI[0.56，1.00]，I=0%）差异有统计学意义。
结论
热毒宁联合 AZM 治疗儿童 MP 可提高临床疗效，安全性高。
Zotero 插件